whitepaper
ebook: Cellular Imaging Insights
Learn how to gain insights and expedite studies for 2D and 3D cellular structures with affordable automated cellular imaging.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
whitepaper
On-demand webinar: Exploring absorbance-based assay applications: From virus to cannabis research
Discover how absorbance detection works as well as different types of absorbance-based assay applications that scientists can utilise for their research.
whitepaper
Article: Imaging dataset for COVID-19 research
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
whitepaper
Interactive demo: Test drive the ImageXpress Pico Automated Cell Imaging System
A powerful, yet affordable, high-content imaging system in your own lab.
whitepaper
ebook: Get a front row view of your cells
Discover how you can simplify your workflow by combining microplate reading and imaging in a small footprint.
news
Researchers target previously “undruggable” enzyme to treat Duchenne muscular dystrophy in cells
By targeting a previously undiscovered allosteric site on a DMD-associated enzyme, researchers found muscle cell conditions improved.
article
NGS: offering a glimmer of hope in the fight against COVID-19
Next-generation sequencing (NGS) has become the method of choice for many researchers responding to infectious disease outbreaks and in the present coronavirus pandemic. Here, Pushpanathan Muthuirulan discusses the potential of NGS for rapid diagnosis and explores some of the emerging high-throughput approaches using NGS as a readout for the detection…
whitepaper
Application note: 3D cell panel screens for drug discovery and development
Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In this application note they demonstrate the ability of parallel 2D and 3D OncoSignature primary screens to identify known compounds with enhanced activity under 3D conditions.
news
Concanamycin A antibiotic that targets Nef protein could cure HIV
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
whitepaper
Webinar series: Considerations for successful CRISPR-based cell line engineering
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
video
On-demand webinar: Leveraging advances in predesigned synthetic sgRNA for highly functional and specific CRISPR-Cas9 gene knockout
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
article
Expert view: Where are you seeing changes in the flow cytometry market?
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
article
Expert view: Why you should use 3D models for high-throughput drug development screens
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
whitepaper
Article: Tips for successful editing in T cells
Horizon article on the recipe for success for CRISPR editing in T cells.
